Core Viewpoint - The company is focusing on building a global health ecosystem through "platform integration and diagnostic integration," enhancing international business from "single-point cooperation" to "ecological collaboration" [2] Group 1: International Strategy - The company aims for significant development in overseas markets by 2025, steadily expanding its business footprint and improving global resource allocation efficiency [2] - The acquisition of Germany's inno-train Diagnostik GmbH in January is a key strategic move to strengthen the company's global presence in high-end blood molecular diagnostics [2] Group 2: Financial Practices - The company places high importance on asset impairment and goodwill assessment, ensuring that annual financial data strictly adheres to accounting standards and is audited [2]